<p>新加坡，2026 年 1 月 28 日（GLOBE NEWSWIRE）——CytoMed Therapeutics Limited（纳斯达克：GDTC）（“CytoMed” 或 “公司”）是一家总部位于新加坡的临床阶段生物制药公司，专注于利用其专有技术开发新型经济实惠的供体来源细胞免疫疗法，以治疗包括血液肿瘤和实体肿瘤在内的广泛癌症。今天，公司发布声明，回应近期关于公司研究项目、临床进展和运营的错误和误导性声明。</p>
<p>CytoMed 坚决拒绝这些毫无根据的声明。某些公开传播的声明错误地描述了公司的科学重点、开发状态和监管地位。请参考公司关于我们进展的最新公告。</p>
<p>CytoMed 的研究专注于基于已建立的免疫学科学的 CAR γδ T 细胞疗法和 iPSC 衍生的γδ NKT 细胞疗法。公司的主要 CAR γδ T 细胞项目已获得监管批准，正在新加坡国立大学医院（NUH）进行首次人体（FIH）临床试验，该临床活动符合适用的监管和伦理要求。</p>
<p>其他项目，包括 iPSC 衍生的γδ NKT 细胞候选者，仍处于临床前开发阶段。CytoMed 并不声称其任何治疗候选者已获得商业使用批准或在其当前开发阶段之外经过临床验证。</p>
<p>关于 CytoMed 的监管状态、制造能力、治理或财务透明度的声明，如果与上述事实相矛盾，则是不准确的或被断章取义，旨在影响公司的股价。公司在遵守适用法规的情况下运营，并遵循适合其阶段的开发实践。</p>
<p>CytoMed 仍致力于负责任地推进其产品管线，并通过公司官方披露传达准确、及时的信息。公司保留采取适当措施以应对可能对其声誉或利益相关者产生不利影响的虚假或误导性信息传播的权利。</p>
<p>股东可以联系以下人员以获取澄清。</p>
<p><strong>关于 CytoMed Therapeutics Limited（CytoMed）</strong></p>
<p>CytoMed 成立于 2018 年，源自新加坡公共部门领先的研究与开发机构科学技术研究局（A*STAR）。CytoMed 是一家临床阶段生物制药公司，专注于利用其获得许可的专有技术，即伽马δ T 细胞和 iPSC 衍生的伽马δ自然杀伤 T 细胞，创造新型细胞基础的同种异体免疫疗法，以治疗各种人类癌症。新技术的开发受到现有 CAR-T 疗法在治疗血液恶性肿瘤方面的临床成功的启发，同时也考虑到将 CAR-T 原理推广到实体肿瘤治疗中的当前临床局限性和商业挑战。有关更多信息，请访问 www.cytomed.sg，并在 Twitter（“X”）上关注我们 @CytomedSG，在 LinkedIn 和 Facebook 上关注我们。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。前瞻性声明包括有关计划、目标、策略、未来事件或表现及其基本假设的声明，以及其他非历史事实的声明。当公司使用 “可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计” 或类似表达时，这些表达并不单纯与历史事项相关，而是在做出前瞻性声明。前瞻性声明并不保证未来表现，并涉及可能导致实际结果与公司在前瞻性声明中讨论的预期大相径庭的风险和不确定性。这些声明受到不确定性和风险的影响，包括但不限于以下内容：公司开发和商业化其产品候选者的计划；公司当前和未来的临床前研究和临床试验的启动、时间、进展和结果，以及公司的研发项目；公司对费用、未来收入、资本需求和额外融资需求的估计；公司成功获取或获得额外产品候选者的许可的能力；公司建立和维持合作关系和/或获得额外资金的能力，以及与上述任何内容相关的假设和其他风险，这些风险在公司向 SEC 提交的报告中有详细说明。基于这些原因，投资者被警告不要对本新闻稿中的任何前瞻性声明过于依赖。其他因素在公司向 SEC 提交的文件中进行了讨论，这些文件可在 www.sec.gov 上查阅。公司没有义务公开修订这些前瞻性声明，以反映此后发生的事件或情况。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的邀请，也不应在任何法律规定禁止此类要约、邀请或销售的司法管辖区内出售这些证券，除非在该司法管辖区的证券法下进行注册或资格审查。</p>
<p><strong>联系方式：</strong></p>
<p><strong>CytoMed Therapeutics Limited</strong></p>
<p>enquiry@cytomed.sg</p>
<p>注意：Evelyn Tan，首席企业官</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5EUTJNeU0zTXprMk5qYzNJekl5TmpFME5ERT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5EUTJNeU0zTXprMk5qYzNJekl5TmpFME5ERT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YTdhZTUtYzA5Yy00YTFhLTkzZmUtMmM0MmFhZjg3YTE1LTEyNzI5OTEtMjAyNi0wMS0yOC1lbg==/tiny/CYTOMED-THERAPEUTICS-LIMITED.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YTdhZTUtYzA5Yy00YTFhLTkzZmUtMmM0MmFhZjg3YTE1LTEyNzI5OTEtMjAyNi0wMS0yOC1lbg==/tiny/CYTOMED-THERAPEUTICS-LIMITED.png"/></p>

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

新细胞医学

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

标普生物技术 ETF - SPDR

<p>CytoMed Therapeutics Limited（纳斯达克代码：GDTC）已发布声明，驳斥关于其研究和临床进展的误导性说法。该公司强调其专注于 CAR γδ T 细胞疗法和 iPSC 衍生的γδ NKT 细胞疗法，目前其主要的 CAR γδ T 细胞项目正在进行首次人体临床试验。CytoMed 声称，任何与其声明相矛盾的关于其监管状态或财务透明度的说法都是不准确的。该公司仍致力于负责任的发展和与利益相关者的准确沟通</p>

<p>SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company’s research programs, clinical progress, and operations.</p>
<div class="lb-trans"><p>新加坡，2026 年 1 月 28 日（GLOBE NEWSWIRE）——CytoMed Therapeutics Limited（纳斯达克：GDTC）（“CytoMed” 或 “公司”）是一家总部位于新加坡的临床阶段生物制药公司，专注于利用其专有技术开发新型经济实惠的供体来源细胞免疫疗法，以治疗包括血液肿瘤和实体肿瘤在内的广泛癌症。今天，公司发布声明，回应近期关于公司研究项目、临床进展和运营的错误和误导性声明。</p>
</div><p>CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress.</p>
<div class="lb-trans"><p>CytoMed 坚决拒绝这些毫无根据的声明。某些公开传播的声明错误地描述了公司的科学重点、开发状态和监管地位。请参考公司关于我们进展的最新公告。</p>
</div><p>CytoMed’s research is focused on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, based on established immunological science. The Company’s lead CAR γδ T cell program has received regulatory approval to proceed with a first-in-human (FIH) clinical trial, which is currently ongoing at National University Hospital (NUH), Singapore. This clinical activity is conducted in accordance with applicable regulatory and ethical requirements.</p>
<div class="lb-trans"><p>CytoMed 的研究专注于基于已建立的免疫学科学的 CAR γδ T 细胞疗法和 iPSC 衍生的γδ NKT 细胞疗法。公司的主要 CAR γδ T 细胞项目已获得监管批准，正在新加坡国立大学医院（NUH）进行首次人体（FIH）临床试验，该临床活动符合适用的监管和伦理要求。</p>
</div><p>Other programs, including iPSC-derived γδ NKT cell candidates, remain in preclinical development. CytoMed does not claim that any of its therapeutic candidates are approved for commercial use or clinically validated beyond their current stage of development.</p>
<div class="lb-trans"><p>其他项目，包括 iPSC 衍生的γδ NKT 细胞候选者，仍处于临床前开发阶段。CytoMed 并不声称其任何治疗候选者已获得商业使用批准或在其当前开发阶段之外经过临床验证。</p>
</div><p>Assertions regarding CytoMed’s regulatory status, manufacturing capabilities, governance, or financial transparency that contradict the above facts are inaccurate or taken out of context and designed to affect the Company’s share price. The Company operates in compliance with applicable regulations and follows development practices appropriate for its stage.</p>
<div class="lb-trans"><p>关于 CytoMed 的监管状态、制造能力、治理或财务透明度的声明，如果与上述事实相矛盾，则是不准确的或被断章取义，旨在影响公司的股价。公司在遵守适用法规的情况下运营，并遵循适合其阶段的开发实践。</p>
</div><p>CytoMed remains committed to advancing its pipeline responsibly and to communicating accurate, timely information through official Company disclosures. The Company reserves the right to take appropriate action to address the dissemination of false or misleading information that may adversely affect its reputation or stakeholders.</p>
<div class="lb-trans"><p>CytoMed 仍致力于负责任地推进其产品管线，并通过公司官方披露传达准确、及时的信息。公司保留采取适当措施以应对可能对其声誉或利益相关者产生不利影响的虚假或误导性信息传播的权利。</p>
</div><p>Shareholders can contact the below person for clarification.</p>
<div class="lb-trans"><p>股东可以联系以下人员以获取澄清。</p>
</div><p><strong>About CytoMed Therapeutics Limited (CytoMed)</strong></p>
<div class="lb-trans"><p><strong>关于 CytoMed Therapeutics Limited（CytoMed）</strong></p>
</div><p>Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.</p>
<div class="lb-trans"><p>CytoMed 成立于 2018 年，源自新加坡公共部门领先的研究与开发机构科学技术研究局（A*STAR）。CytoMed 是一家临床阶段生物制药公司，专注于利用其获得许可的专有技术，即伽马δ T 细胞和 iPSC 衍生的伽马δ自然杀伤 T 细胞，创造新型细胞基础的同种异体免疫疗法，以治疗各种人类癌症。新技术的开发受到现有 CAR-T 疗法在治疗血液恶性肿瘤方面的临床成功的启发，同时也考虑到将 CAR-T 原理推广到实体肿瘤治疗中的当前临床局限性和商业挑战。有关更多信息，请访问 www.cytomed.sg，并在 Twitter（“X”）上关注我们 @CytomedSG，在 LinkedIn 和 Facebook 上关注我们。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&amp;D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。前瞻性声明包括有关计划、目标、策略、未来事件或表现及其基本假设的声明，以及其他非历史事实的声明。当公司使用 “可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计” 或类似表达时，这些表达并不单纯与历史事项相关，而是在做出前瞻性声明。前瞻性声明并不保证未来表现，并涉及可能导致实际结果与公司在前瞻性声明中讨论的预期大相径庭的风险和不确定性。这些声明受到不确定性和风险的影响，包括但不限于以下内容：公司开发和商业化其产品候选者的计划；公司当前和未来的临床前研究和临床试验的启动、时间、进展和结果，以及公司的研发项目；公司对费用、未来收入、资本需求和额外融资需求的估计；公司成功获取或获得额外产品候选者的许可的能力；公司建立和维持合作关系和/或获得额外资金的能力，以及与上述任何内容相关的假设和其他风险，这些风险在公司向 SEC 提交的报告中有详细说明。基于这些原因，投资者被警告不要对本新闻稿中的任何前瞻性声明过于依赖。其他因素在公司向 SEC 提交的文件中进行了讨论，这些文件可在 www.sec.gov 上查阅。公司没有义务公开修订这些前瞻性声明，以反映此后发生的事件或情况。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的邀请，也不应在任何法律规定禁止此类要约、邀请或销售的司法管辖区内出售这些证券，除非在该司法管辖区的证券法下进行注册或资格审查。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>CytoMed Therapeutics Limited</strong></p>
<div class="lb-trans"><p><strong>CytoMed Therapeutics Limited</strong></p>
</div><p>enquiry@cytomed.sg</p>
<div class="lb-trans"><p>enquiry@cytomed.sg</p>
</div><p>Attention: Evelyn Tan, Chief Corporate Officer</p>
<div class="lb-trans"><p>注意：Evelyn Tan，首席企业官</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5EUTJNeU0zTXprMk5qYzNJekl5TmpFME5ERT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0NDQ2MyM3Mzk2Njc3IzIyNjE0NDE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YTdhZTUtYzA5Yy00YTFhLTkzZmUtMmM0MmFhZjg3YTE1LTEyNzI5OTEtMjAyNi0wMS0yOC1lbg==/tiny/CYTOMED-THERAPEUTICS-LIMITED.png" alt="" original-src="https://ml.globenewswire.com/media/M2M2YTdhZTUtYzA5Yy00YTFhLTkzZmUtMmM0MmFhZjg3YTE1LTEyNzI5OTEtMjAyNi0wMS0yOC1lbg==/tiny/CYTOMED-THERAPEUTICS-LIMITED.png"/></p>

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | GDTC Stock News

StockTitan

Invesco Nasdaq Biotechnology ETF

新细胞医学驳斥误导性声明并重申其临床进展 | GDTC 股票新闻